Cyfuse Biomedical K.K. (TYO:4892)
Japan · Delayed Price · Currency is JPY 570.00
0.00 (0.00%)
Aug 27, 2026, 3:30 PM JST
Cyfuse Biomedical K.K. Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 3,391 | 3,726 | 3,052 | 3,873 | 4,437 | 2,413 |
Cash & Short-Term Investments | 3,391 | 3,726 | 3,052 | 3,873 | 4,437 | 2,413 |
Cash Growth | 25.69% | 22.08% | -21.20% | -12.71% | 83.88% | 16.46% |
Accounts Receivable | 2 | 5 | 20 | 17 | 13 | 57 |
Other Receivables | 14 | 40 | 43 | 32 | 56 | - |
Receivables | 16 | 45 | 63 | 49 | 69 | 57 |
Inventory | 73 | 88 | 55 | 46 | 40 | 61 |
Prepaid Expenses | 82 | 72 | 51 | 16 | 17 | 5 |
Other Current Assets | 3 | 3 | 19 | 3 | 2 | 22 |
Total Current Assets | 3,565 | 3,934 | 3,240 | 3,987 | 4,565 | 2,558 |
Property, Plant & Equipment | 143 | 155 | 141 | 169 | 189 | 27 |
Long-Term Investments | 214 | 173 | 131 | 53 | 55 | 55 |
Other Intangible Assets | 2 | 3 | 4 | 4 | 5 | 4 |
Other Long-Term Assets | 1 | 1 | 2 | 1 | 1 | 2 |
Total Assets | 3,925 | 4,266 | 3,518 | 4,214 | 4,815 | 2,646 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4 | 69 | 15 | 2 | 4 | 8 |
Accrued Expenses | 8 | 12 | 16 | 19 | 25 | 6 |
Short-Term Debt | 415 | 485 | 507 | 550 | 467 | 128 |
Current Portion of Long-Term Debt | 434 | 184 | 18 | 18 | 77 | 72 |
Current Portion of Leases | - | - | - | - | - | 8 |
Current Income Taxes Payable | 48 | 63 | 59 | 47 | 74 | 74 |
Current Unearned Revenue | - | - | 20 | 19 | 22 | 19 |
Other Current Liabilities | 11 | 53 | 13 | 11 | 13 | 71 |
Total Current Liabilities | 920 | 866 | 648 | 666 | 682 | 386 |
Long-Term Debt | 383 | 642 | 327 | 345 | 363 | 359 |
Other Long-Term Liabilities | - | 2 | 1 | 1 | 1 | 1 |
Total Liabilities | 1,303 | 1,510 | 976 | 1,012 | 1,046 | 746 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1,965 | 1,828 | 1,364 | 1,283 | 1,272 | 100 |
Additional Paid-In Capital | 4,587 | 4,450 | 3,986 | 3,905 | 3,893 | 2,721 |
Retained Earnings | -4,056 | -3,622 | -2,858 | -1,986 | -1,396 | -922 |
Comprehensive Income & Other | 126 | 100 | 50 | - | - | 1 |
Shareholders' Equity | 2,622 | 2,756 | 2,542 | 3,202 | 3,769 | 1,900 |
Total Liabilities & Equity | 3,925 | 4,266 | 3,518 | 4,214 | 4,815 | 2,646 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1,232 | 1,311 | 852 | 913 | 907 | 567 |
Net Cash (Debt) | 2,159 | 2,415 | 2,200 | 2,960 | 3,530 | 1,846 |
Net Cash Growth | 11.75% | 9.77% | -25.68% | -16.15% | 91.22% | 19.48% |
Net Cash Per Share | 222.97 | 274.37 | 273.27 | 378.89 | 1323.28 | 3688.31 |
Filing Date Shares Outstanding | 10.06 | 9.62 | 8.14 | 7.83 | 6.44 | 0.5 |
Total Common Shares Outstanding | 10.06 | 9.62 | 8.14 | 7.83 | 6.44 | 0.5 |
Working Capital | 2,645 | 3,068 | 2,592 | 3,321 | 3,883 | 2,172 |
Book Value Per Share | 260.59 | 286.63 | 312.31 | 409.12 | 585.09 | 3796.20 |
Tangible Book Value | 2,620 | 2,753 | 2,538 | 3,198 | 3,764 | 1,896 |
Tangible Book Value Per Share | 260.39 | 286.31 | 311.82 | 408.60 | 584.31 | 3788.21 |